Equities

Aroa Biosurgery Ltd

Aroa Biosurgery Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.63
  • Today's Change0.00 / 0.00%
  • Shares traded106.13k
  • 1 Year change-10.00%
  • Beta1.1687
Data delayed at least 20 minutes, as of Nov 18 2024 04:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement, and complex wounds.

  • Revenue in AUD (TTM)62.61m
  • Net income in AUD-9.63m
  • Incorporated2007
  • Employees261.00
  • Location
    Aroa Biosurgery Ltd64 Richard Pearse Drive, MangereAUCKLAND 2022New ZealandNZL
  • Phone+64 98693035
  • Websitehttps://aroa.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Respiri Ltd1.04m-7.13m117.48m2.00--39.57--113.12-0.007-0.0070.0010.00230.22160.0026.91---152.14-153.06-384.52-255.3469.98---686.48-617.730.3744-108.650.0423--56.850.1379-23.44------
SDI Ltd111.21m10.42m127.78m300.0012.261.368.751.150.08770.08770.93560.79060.81181.555.51--7.617.139.328.4062.0859.869.378.191.408.010.208746.683.116.9247.697.2911.964.72
EchoIQ Ltd44.50k-5.41m132.42m----17.87--2,975.67-0.0109-0.01090.000090.01260.0048--0.1208---58.04-65.22-76.45-83.27-----12,155.39-1,722.30----0.00---58.54-44.2334.56------
Optiscan Imaging Ltd1.16m-6.06m142.01m8.00--10.24--122.89-0.0074-0.00740.00140.01660.11380.30620.9086---59.70-49.52-70.78-58.8454.4616.53-524.45-312.657.45--0.0157---31.221.91-39.27--80.89--
Orthocell Ltd6.76m-7.18m149.45m----28.86--22.09-0.0356-0.03560.03350.02170.24061.479.37---25.55-28.99-30.96-34.0275.9571.10-106.16-242.964.11--0.1321--32.7947.88-14.93--20.63--
Cyclopharm Limited29.04m-9.32m150.59m87.00--3.17--5.19-0.0976-0.09760.30660.42780.51211.114.01333,756.60-16.43-12.60-19.97-14.9464.7770.20-32.08-25.473.42-37.570.1049--11.2215.5028.90---7.83-12.94
Genetic Signatures Ltd14.27m-17.86m156.54m----2.43--10.97-0.1124-0.11240.08640.28380.24531.023.20---30.70-11.57-34.00-12.6944.5655.89-125.15-25.418.76-509.340.0196---35.2914.72-27.11--50.98--
Medadvisor Ltd122.11m792.13k165.39m100.00197.373.2033.161.350.00150.00150.22280.09371.25--11.12--0.8137-15.721.37-24.6060.8159.350.6487-15.38--1.520.1964--24.6467.75107.01--77.57--
EMvision Medical Devices Ltd11.56m-2.73m165.47m----8.93--14.31-0.033-0.0330.14370.21680.6515-------15.38-47.89-20.97-59.47-----23.61-100.24---16.560.1354--62.9959.0629.48------
Anteris Technologies Ltd7.14m-87.90m190.26m1.00--30.46--26.65-5.04-5.040.41220.29550.23613.235.01---304.00-120.86-529.47-189.2768.4366.40-1,287.57-316.850.9233-132.480.3869--4.48-22.85-51.86--42.27--
4DMedical Ltd3.75m-35.98m199.11m----2.81--53.04-0.0972-0.09720.01010.17280.03530.28570.5844---33.79-39.81-41.36-50.9093.6967.64-958.34-1,941.161.74--0.0673--422.4640.12-14.36---1.77--
Aroa Biosurgery Ltd62.61m-9.63m217.29m261.00--2.52--3.47-0.028-0.0280.18210.250.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Imricor Medical Systems Inc1.28m-31.41m218.84m--------171.29-0.1842-0.18420.0073-0.04920.10410.85013.78---255.91-93.47-387.91-106.30-110.81-134.71-2,458.30-2,462.890.799-4.554.73---24.56-9.29-30.36---10.82--
Data as of Nov 18 2024. Currency figures normalised to Aroa Biosurgery Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

23.08%Per cent of shares held by top holders
HolderShares% Held
Harbour Asset Management Ltd.as of 23 Aug 202430.34m8.80%
Acorn Capital Ltd.as of 23 Aug 202422.49m6.52%
Wilson Asset Management (International) Pty Ltd.as of 30 Jun 202410.87m3.15%
Guardians of New Zealand Superannuationas of 30 Jun 20235.39m1.56%
Mirrabooka Investments Ltd. (Investment Management)as of 30 Jun 20244.92m1.43%
Norges Bank Investment Managementas of 30 Jun 20243.44m1.00%
DFA Australia Ltd.as of 30 Sep 20241.32m0.38%
Dimensional Fund Advisors LPas of 31 Jul 2024657.91k0.19%
FCA Corp.as of 30 Sep 2024145.00k0.04%
Dimensional Fund Advisors Ltd.as of 07 Nov 202452.91k0.02%
More ▼
Data from 30 Jun 2023 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.